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stimulated the right carotid sinus by applying pressure with 
her hand or pillow when adopting her usual sleeping posture. 
Carotid sinus syndrome is an underdiagnosed cause of 
dizziness, falls, and syncope in the elderly. It is present in 
almost half the patients seen at syncope clinics.1 As in our 
patient3 the right side is involved more frequently than the 
left.1^  In  addition to commonly described triggering factors 
such as head movements, local pressure, and local tumours, a 
number of unusual triggering factors have been noted such as 
prolonged standing, eating, micturition, defaecation, 
coughing, and exertion.1 Few conditions produce recumbent 
syncope. These include the supine hypotensive syndrome of 
late pregnancy as a result of inferior vena cava compression,1 
syncope during dental surgical procedures attributed to reflex 
parasympathetic activity caused by trigeminal nerve 
stimulation,5 and, rarely, atrial myxomas, As this case 
illustrates, carotid sinus syndrome can present in unusual 
ways. It is a treatable cause of recumbent syncope in the 
elderly.
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Fluoxetine and chronic fatigue syndrome
Sir—The importance of Vercoulen and colleagues’ (March
30, p 858)1 investigation of the cffect of fluoxetine treatment 
in chronic fatigue syndrome (CFS) cannot be 
underestimated, since between 0-5% and 1*5% of the 
population have this condition,3 Unfortunately, the data as 
presented suggest that this study does not generalise to most 
patients with CFS,
The first difficulty relates to the method of excluding 
psychiatric disorder other than depression in these patients. 
We are told that a structured psychiatric interview was given. 
Without details, it is unclear how people with somatisation 
disorder (SD) were excluded, which is important because, 
strictly speaking, such a diagnosis rules out that of CFS. 
Furthermore, the treatment response of SD is notoriously 
poor, Our second point relates to the length of illness in this 
sample, Individuals are included with illness durations up to 
30 years, with the median being around 6 years. It is 
probable that this is a severely ill group of patients, since both 
community and tertiary care samples have average illness 
durations of around half this lengtii. Finally, we are not told 
whether patients have previously tried or been unresponsive 
to other effective treatments such as cognitive-behavioural 
therapy.
One of the puzzling findings of the study is the absence of 
any placebo response in these patients. This result is in 
striking contrast with previous open studies of 
antidepressants (or other tiierapies) in CFS, in which rates
are very high. There are grounds to suspect that the 
individuals entered into this study were a severe and 
unresponsive sample, with possibly a high frequency of 
undetected SD. Thus the results may not apply to those with 
the more commonly encountered forms of CFS. It is also 
possible to postulate that an important therapeutic response 
in CFS of such long duration requires more than 8 weeks of 
treatment, or some additional rehabilitative therapy. 
Preliminary results from a similar study comparing 
fluoxetine, placebo, and graded exercise showed that both 
active treatments were effective,’
Additionally, we would not wish to discount the possible 
role of serotonergic abnormalities in CFS. Studies 
attempting accurately to assess serotonergic function in CFS 
patients must exclude comorbid psychiatric disorders such as 
depression, since these disorders can themselves affect 
serotonergic function/ We tested non-depressed CFS 
patients with the prolactin response to d-fenfluramine as an 
index of functional 5-hydroxytryptamine (5HT) 
neurotransmission.'1 There was evidence of serotonergic 
supersensitivity in CFS, and subsensitivity in a group of 
depressed patients, compared with healthy controls/ 
Serotonergic supersensitivitiy in CFS was also shown by 
Bakheit et aP who assessed 5HT receptor function.
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Sir—Vercoulen and co-workers1 assess fatigue solely by a 
subjective rating scale, and therefore fail to recognise that 
such indices may be confounded by a modified perception of 
effort3 pain, and fatigue in CFS patients. In formal studies of 
neuromuscular function in CFS, there was evidence of a 
dissociation between subjective and objective reports of 
muscle dysfunction, with no major changes in peripheral 
muscle function associated with the perceived muscle 
weakness,2 Clearly a more rigorous and objective means of 
assessing fatiguability (for example, exercise testing) is 
needed to establish whether fluoxetine and related drugs 
influence the underlying fatigue process in CFS. Ambulatory 
activity as measured in 5-minute bins with an Ac to meter 
strapped to the ankle, is in our view not sufficient for these 
purposes.
Regarding the measurement of depression severity, the 
Beck depression inventory (BDI) was the preferred method 
of rating depression before and alter fluoxetine treatment, 
and at follow-up. The B D I is not a diagnostic tool and 
contains important items on cognitive and somatic factors, as 
well as affect. Despite the fact that fatigue and loss of energy 
were excluded from the BD I score calculation, it should be 
noted that a score of 16 or more (indicative of depression in 
this study) can be achieved with low scores on the affect 
subscale. An improvement in depressive symptoms over the
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course of treatment under such circumstances may not be 
possible. Vercoulen and colleagues have tried to address this 
issue by analysing affective, cognitive, and somatic subset 
scores independently in both the fluoxetine and placebo 
condition. However, since they do not provide absolute 
subset scores it is not possible to deduce the degree to which 
somatic and cognitive factors obscure any changes in affect 
during the study. We were also surprised by the apparent 
lack of a placebo effect in this double-blind study. Since one 
would expect a 20-30% change in symptomatology 
attributable to such an effect.
Finally, we feel it necessary to point out that substantial 
evidence in published work points to a link between the 5HT 
system and the fatigue process. Exercise is accompanied by 
5HT release. * Bakheit and colleagues1 have demonstrated an 
upregulation of hypothalamic 5HT receptors in CFS, as 
evidenced by a supersensitivc prolactin response to buspirone 
(a partial 5HT ,U agonist). Our group has recently shown that 
endurance-trained athletes have a significantly reduced 
prolactin response to buspirone, compared with untrained 
controls,'' suggesting that the repeated activation of the 5HT 
system during endurance training may lead to a 
downregulation of 5H TU receptors and improved exercise 
tolerance.
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vStU We were intrigued by several aspects of Vercoulen and 
colleagues’ study.1 There seems to be little or no placebo 
response in either the CFS group with depression of the CFS 
group without depression. This finding was somewhat 
surprising in view of the placebo responses described in 
reports in previous studies of immunotherapy,3 antiviral 
therapy/ and magnesium injections’ in patients with CFS. 
There was actually a considerable negative placebo response 
in the CFS depressed group (26%), probably not 
significantly different from the numbers in the CFS 
depressed group deteriorating while on fluoxetine. We 
wondered if this low positive placebo response might be 
partly accounted for by the chronicity of symptoms in the 
group studied. These findings if replicated, would have 
important implications for research design in studies of
antidepressant treatment in CFS.
The alternative explanation of the finding is that these 
responses could indicate the illness attributions of patients. If 
patients were to believe that antidepressant response would 
suggest a psychological cause to their complaints, this may 
well be reflected in a nocebo (negative placebo) response. 
This might be especially important if patients have strongly 
held physical attributions of illness causation. In view of the
fact that some studies reported an association between these 
types of attribution and chronic affective disorder in CFS ,5 
this is a plausible explanation for the above findings. We 
wondered if Vercoulen and co-workers are in a position to 
address this possible explanation for the low overall rate of 
placebo response.
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Author's reply
Sir— C leare and Wessely’s main theme is that our patients 
were an unresponsive sample because of the long duration of 
their illness. In two prospective studies on the natural course 
in CFS patients with a similar length of illness we found that 
after 1*5 years improvement rate was 20% ‘ and after 4-5 
years about 35% (Bazelmans E et al, unpublished). In  
addition, a similar group of patients, randomly selected from 
the same database, participated in cognitive-behavioural 
treatment and showed positive results, On the basis of these 
findings we conclude that these patients may well respond to 
treatment. They also argue that we might have included 
patients with SD. However, in a strict sense the diagnosis SD 
is not a reason for rejecting CFS according to British criteria2 
or to the recent Centers for Disease Control and Prevention 
criteria,1 Moreover, SD is a descriptive diagnosis based on a 
number of rather arbitrarily chosen symptoms, and merely 
reflects patients with multiple physical symptoms for which 
no explanation can be offered. In  a prospective study of our 
group number of complaints was no predictor for the course 
of complaints.1 Thus, it is unlikely that SD influenced results.
All your correspondents refer to the absence of a placebo 
response in the fluoxetine-treated patients. In the placebo- 
treated patients a normal placebo effect is seen in depression 
severity, but in fluoxetine patients a placebo effect is absent. 
This finding may suggest that fluoxetine in fact has a 
detrimental effect. This effect could well be due to the fact 
that fluoxetine is a serotonin reuptake inhibitor; two studies 
have shown that in CFS there may be serotonergic 
hypersensitivity,1[A and from tiiat perspective fluoxetine would 
do harm. Lynch and Sedi’s hypothesis as an explanation for 
the absence of a placebo effect seems unlikely because 
fluoxetine has been presented to the patient as a drug with a 
general effect on somatic processes, being effective in 
depression and possibly in fatigue. Thus, the drug was 
related to an effect on physical processes, and we did not 
suggest that the cause of complaints would be psychological.
W ith respect to Sharma and colleagues’ points, first* we do 
not favour exercise testing as a means of measuring fatigue. 
Results of such tests are difficult to interpret because they are 
susceptible to confounding factors, such as physical 
deconditioning. Accelerometers, as we used them, yield 
highly reliable data and have been reported to be valid 
instruments measuring hum an physical activity, close
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correlations were found with energy expenditure. In 
addition, the accelerometer provides measurements of 
physical activity during natural conditions and for long 
periods j and such data are clinically more important than 
laboratory-induced activities, We feel that die value of 
treatment of CFS especially should relate to clinical 
characteristics such as subjective feeling of fatigue and 
activity in daily life. Second, the use of a severity measure of 
depression in psychopharmacological research is not 
unusual. The use of the BDI on the other hand is not that 
common, but this method has excellent psychometric 
properties and can measure change. It is true that cognitive 
and somatic symptoms are components of the BDI score, bur 
this is also true for the diagnosis major depression. Thus, 
deleting tiiese symptom groups in both the BD I and the 
diagnosis would destroy the concept of depression.
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Epidemiological perspectives on alcohol and 
the law
Sir—In their April 13 commentary Alvarez and Del Rio1 
raise the contradictions of modem medicine when diey 
attempt to address social problems: why is it that, as 
epidemiologists, we should excel at sophisticated evaluation 
when die effects of cholesterol-lowering drug dierapy, oral 
contraceptives or calcium inhibitors need assessing, but we 
are satisfied widi the weakest of evidence when denouncing 
the assumed effects of alcohol on driving ability?
I have just returned from an 800 km trip on French 
motorways. I travelled at a constant 130 km/h, the maximum 
permitted limit. Throughout this trip* I overtook not more 
than ten cars. In practice, this means that more dian 99% of 
cars travelling in the same direction as I was were blatantly 
exceeding the speed limit. And what about other dangerous 
behaviour, such as using the mobile phone (at 180 km/h), or 
not respecting safe distances between vehicles (or both at 
once)? When the law can be so regularly and flagrantly 
broken, I must admit to some difficulty in believing that 
respect for public order necessitates systematic checks of 
matters as private as consumption of alcohol. The paradox of 
road safety today is that the state seems to want to set limits 
for individuals (eg, checking their drinking habits), while 
giving up any idea of applying the law convincingly (eg, 
cracking down on such obvious illegal behaviour as 
exceeding the speed limit). Besides ethical issues raised by 
drink-driving tests, there is die difficulty of epidemiological 
justification: what proof exists of their efficacy? And who is
capable of evaluating the importance of blood alcohol levels, 
in relation to all risk factors involved in driving accidcnts? 
Having personally been in both situations, I honestly believe 
I am less dangerous on the road with a 0*5 g/L blood alcohol 
level, than when I have been working all night. In France, 
where drinking at meals is an important part of social life, it is 
hard for people to accept tiiat one may be punished for 
drinking three glasses of wine, when everyone knows it is 
possible to go from Paris to Marseille at 200 km/h with little 
risk of being fined. The result is a complete breakdown of 
social consensus about driving behaviour, whose logical 
consequence is diat state of anarchy illustrated by my recent 
experience: the population is less and less aware of the 
hierarchy of risks.
Now a signal function of epidemiology is to address 
distortions in perceived risks— we are not working in the 
public interest at all if all we do is to take on board what 
politicians are saying about drink-driving, without looking at 
it critically. Resistance to the effects of alcohol is, as everyone 
knows, highly idiosyncratic. Courage in epidemiology today, 
dierefore, consists in stating that doing away with preventive 
checks is perfectly compatible widi die requirements of 
public health, provided that blood alcohol tests are applied 
systematically after any highway offence, however minor. 
The impact of such a change on die way people think would 
be considerable. Whereas at present die detection of a 
proscribed level of blood alcohol does not go down well 
because everybody knows that it does not prove a state of 
danger, to check a posteriori would place die burden of proof 
on the driver, since every single time there was alcohol in the 
blood an offence would be linked with it. Such a situation, in 
which a high degree of alcohol consumption became 
synonymous with offences committed, would undoubtedly 
contribute to rebuilding the social consensus that is so badly 
lacking in die struggle against dangerous driving.
Marc Girard
Conaell en Pharmacovlgllance et PharmacoGpldemiologie, 78000 Versailles, France
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Benign adipic aciduria
Sir—A 5-year-old girl from the former German Democratic 
Republic suspected of having Kearn-Sayres Syndrome was 
admitted to our department for diagnostic examination. On 
routine examination of organic acids in urine she was found 
to be excreting massive amounts of adipic acid but 
surprisingly without substantial amounts of suberic, sebacic, 
or ethylmalonic acids. Adipic acid excretion accompanied by 
these other metabolites is often a sign of several metabolic 
diseases. This perplexing finding was repeated in successive 
urine samples and seemed to have no relation to time of day 
or meals. Discussion with the mother, die child herself, 
nurses, and physicians gave no explanation for this metabolic 
pattern. During her stay die child developed a metabolic 
crisis requiring infusion of fluids and electrolytes. Under 
these conditions the adipic acid excretion disappeared. This 
was even more perplexing but did suggest that die adipic acid 
had something to do with her oral intake. In agreement with 
the treating physician the patient had been kept on her 
previous medication. Recourse was finally taken to direct 
examination of the patient’s medications which revealed that 
she was taking K  and Mg in the form of die adipate salt 
(Kalium-Magnesium Apogepha). In die Federal Republic of 
Germany K  and Mg were not previously available as the
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